Drug Trial Radar · NCT04114825
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Nov 19, 2019
Primary completion
Apr 2022
Study completion Nov 2022
Sponsor
- Lead sponsor
- RhoVac APSIndustry
- Sponsor type
- Industry
- First posted
- Oct 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive RT and no distant metastasis or locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (RV001V).
Conditions
- Prostate Cancer Recurrent
Interventions
RV001VBiological
RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
PlaceboOther
Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to PSA progressionTime frame: Up to 3 years
Locations
36 sites in 7 countries. Site status is shown where the registry gives one.
Tampa Bay Medical Research
Clearwater, Florida
Chesapeake Urology Research Associates
Towson, Maryland
GU Research Network/Urology Cancer Center
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Icahn School of Medicine at Mount Sinai Hospitals
New York, New York
Carolina Urologic Research Center
Myrtle Beach, South Carolina
The Urology Place
San Antonio, Texas
Gent University Hospital
Ghent, Belgium
CHU de Liège
Liège, Belgium
Hôpital Erasme
Liège, Belgium
Aalborg University, Departmen of Urology
Aalborg, Denmark
Aarhus University Hospital, Department of Urology
Aarhus, Denmark
Rigshospitalet, Copenhagen Prostate Cancer Center
Copenhagen, Denmark
Herlev & Gentofte Hospital, Department of Urology
Herlev, Denmark
Urinvejskirurgisk afdeling, Hospitalsenheden Vest
Holstebro, Denmark
Odense University Hospital, Deparment of Urology
Odense, Denmark
Meilahti Tower Hospital
Helsinki, Finland
Oulu University Hospital
Oulu, Finland
Seinajoki Central Hospital
Seinäjoki, Finland
Tampere University Hospital
Tampere, Finland
Turku University Hospital
Turku, Finland
University Hospital Dresden
Dresden, Germany
Urologicum Duisburg
Duisburg, Germany
Urologische Praxis Dr. Wolfgang Warnack
Hagenow, Germany
Urologische Praxis. M. Markov
Halle, Germany
Studienpraxis Urologie
Nürtingen, Germany
University Hospital Tuebingen
Tübingen, Germany
Sahlgrenska University Hospital
Gothenburg, Sweden
Skåne University Hospital
Malmö, Sweden
Örebro University Hospital
Örebro, Sweden
Karolinska University Hospital
Stockholm, Sweden
Umeå University Hospital
Umeå, Sweden
Clatterbridge Centre for Oncology
Liverpool, United Kingdom
Royal Free London NHS Foundation Trust Royal Free Hospital
London, United Kingdom
Nottingham University Hospital
Nottingham, United Kingdom
University Hospital Southampton
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.